| Nov 15 |
Checkpoint Therapeutics Third Quarter 2024 Earnings: US$0.23 loss per share (vs US$0.29 loss in 3Q 2023)
|
| Nov 14 |
Checkpoint Therapeutics: Preparing For Cosibelimab's Upcoming PDUFA Date
|
| Nov 12 |
Checkpoint Therapeutics GAAP EPS of -$0.23 misses by $0.08
|
| Nov 12 |
Checkpoint Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
|
| Sep 16 |
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024
|
| Sep 4 |
Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
|
| Aug 27 |
Checkpoint Therapeutics: A Binary Bet On FDA Approval And Cosibelimab's Market Success
|
| Aug 19 |
Checkpoint Therapeutics files secondary offering of up to 5.9M shares
|
| Aug 16 |
What Makes Checkpoint Therapeutics (CKPT) a New Buy Stock
|
| Aug 14 |
Individual investors account for 57% of Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) ownership, while public companies account for 9.8%
|
